PF-08046054 by Pfizer for Ovarian Cancer: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer.

Q&A: The U.S. can, and should, do more on H5N1 bird flu, a top WHO official says

More work needs to be done by the agricultural sector to get to the bottom of — and put a stop to — transmission of H5N1

September 16, 2024

New AI camera technology could offer a future tool for quickly assessing the severity of infections

It might soon be possible to measure a patient’s pulse, breathing, and blood pressure simply by scanning their face.

June 5, 2024

BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance

As BioNTech continues to beef up its oncology pipeline, it’s once again turning to a Chinese partner. The German biotech is putting down $55 million

November 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.